Northwest Biotherapeutics (NWBO) Assets Average (2011 - 2026)

Northwest Biotherapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $80.7 million for Q1 2026.

• On a quarterly basis, Assets Average rose 197.5% year-over-year to $80.7 million in Q1 2026; TTM through Mar 2026 was $80.7 million, a 197.5% increase from a year earlier, with the FY2025 full-year figure at $54.0 million, up 97.86% from the prior year.
• Assets Average grew to $80.7 million in Q1 2026 per NWBO's latest filing, from $55.9 million in the prior quarter.
• Across five years, Assets Average topped out at $80.7 million in Q1 2026 and bottomed at $27.1 million in Q1 2025.
• The 5-year median for Assets Average is $29.7 million (2023), against an average of $34.3 million.
• Across the five-year window, Assets Average decreased 12.09% in 2024 and jumped 197.5% in 2026, its largest moves.
• Year by year, Assets Average stood at $31.2 million in 2022, then fell by 4.91% to $29.7 million in 2023, then retreated by 5.57% to $28.0 million in 2024, then surged by 99.64% to $55.9 million in 2025, then surged by 44.18% to $80.7 million in 2026.
• Per Business Quant, the three latest NWBO Assets Average figures stand at $80.7 million (Q1 2026), $55.9 million (Q4 2025), and $30.1 million (Q3 2025).